Physician profile
Anna Babaie
NPI 1669905568
$1,681.48
in general payments reported to CMS, 2019-2025
18 companies · $53.54 in 2025
The $53.54 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $534 · 2023: $699 · 2024: $395 · 2025: $53.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $326.92 | 2022-2023 | Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $286.82 | 2022 | |
| Abbvie INC. | $226.90 | 2022-2024 | Ubrelvy, Qulipta |
| Ucb, INC. | $208.20 | 2023-2025 | Briviact, Rystiggo, Zilbrysq |
| Ani Pharmaceuticals, INC. | $114.61 | 2023-2024 | Purified Cortrophin Gel |
| Sk Life Science, INC. | $112.73 | 2023-2024 | |
| Amgen INC. | $72.49 | 2024 | Uplizna |
| Neurelis, INC. | $55.66 | 2023-2024 | Valtoco |
| Pfizer INC. | $48.23 | 2023 | |
| Grifols USA, LLC | $38.12 | 2023 | Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $34.37 | 2023 | Gammagard |
| Ge Healthcare | $27.85 | 2024 | |
| Lilly USA, LLC | $25.17 | 2023 | Reyvow, Emgality |
| Alexion Pharmaceuticals, INC. | $25.04 | 2024 | Ultomiris |
| Tanabe Pharma America, INC. | $23.34 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $19.46 | 2024 | Gocovri |
| Boston Scientific Corporation | $18.44 | 2024 | Wavewriter Alpha Prime 16 |
| Octapharma USA, INC. | $17.13 | 2023 | Panzyga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Babaie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.